Dr. Powles on Durvalumab in Urothelial Cancer

Thomas Powles, MD
Published: Monday, Feb 20, 2017



Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Durvalumab, is a selective, high-affinity human IgG1 monoclonal antibody that binds to both PD-1 and CD80.

In a phase Ib trial, durvalumab was associated with long-term durable responses in patients with metastatic bladder cancer patients who have previously failed on chemotherapy. The response rate was between 20% and 30% and there was also responses reported in the PD-L1–negative population.

According to Powles, durvalumab, along with agents like pembrolizumab (Keytruda), have superseded chemotherapy in the second-line.
 


Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Durvalumab, is a selective, high-affinity human IgG1 monoclonal antibody that binds to both PD-1 and CD80.

In a phase Ib trial, durvalumab was associated with long-term durable responses in patients with metastatic bladder cancer patients who have previously failed on chemotherapy. The response rate was between 20% and 30% and there was also responses reported in the PD-L1–negative population.

According to Powles, durvalumab, along with agents like pembrolizumab (Keytruda), have superseded chemotherapy in the second-line.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x